Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Granules-India-Limited"

51 News Found

Granules India and Central Bureau of Narcotics unite to tackle drug abuse
News | June 29, 2023

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society


Granules India received ANDA approval for Metoprolol Succinate ER Tablets
Drug Approval | June 14, 2023

Granules India received ANDA approval for Metoprolol Succinate ER Tablets

Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.


Granules India received ANDA approval for Venlafaxine ER capsules
Drug Approval | May 20, 2023

Granules India received ANDA approval for Venlafaxine ER capsules

Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder


Granules India receives ANDA approval for Gabapentin Tablets
Drug Approval | March 30, 2023

Granules India receives ANDA approval for Gabapentin Tablets

Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults


Granules India inaugurates packaging facility in Virginia
Supply Chain | March 30, 2023

Granules India inaugurates packaging facility in Virginia

The facility is over 79,000 square feet and is equipped with packaging lines


Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg
Drug Approval | February 27, 2023

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.


Granules Pharmaceuticals receives ANDA approval for amphetamine mixed salts ER capsules
Drug Approval | January 25, 2023

Granules Pharmaceuticals receives ANDA approval for amphetamine mixed salts ER capsules

Granules now have a total of 53 ANDA approvals from USFDA


Supriya Lifescience appoints Krishna Raghunathan as CFO
People | January 24, 2023

Supriya Lifescience appoints Krishna Raghunathan as CFO

He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group


Granules India’s Gagillapur facility completes USFDA inspection
Drug Approval | January 16, 2023

Granules India’s Gagillapur facility completes USFDA inspection

The company will respond to these observations within the stipulated time period.


Granules partners with Greenko ZeroC to enable green molecule solutions
Sustainability | January 03, 2023

Granules partners with Greenko ZeroC to enable green molecule solutions

Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.